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In 5 years, 64 solid hepatic lesions have been referred for diagnosis and management which have been
found unexpectedly on organ imaging in well patients. We have called this lesion a "dystychoma".
Patients have undergone a two phase investigation programme which allows a diagnosis without
admission to hospital in about 50% of cases. About three quarters of patients (47/64) have had non-
neoplastic lesions, and about half (33/64) have had haemangiomas. About one patient in four (17/64) has
had a neoplasm, and the neoplasm has been malignant in about one in six (11/64) of all patients.
We stress the need to pursue the diagnosis in these patients. There were no reliable clinical,
biochemical or imaging characteristics which individually distinguished benign from malignant lesions.
Age over 55 years, an enlarged liver or a palpable liver mass and a raised serum alkaline phosphatase
were all significantly more frequent with malignant tumours. The risk of malignancy rose with the
number of risk factors, and all patients with all three risk factors had malignant tumours.
Only 11 of the 64 patients were judged to have benefited by significant increase in quality or quantity
of life as a result of what was frequently inappropriate organ imaging. There is no strong argument for
replacing history taking and physical examination by CT scanning, ultrasound examination or other
organ imaging.
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INTRODUCTION
In 1990, members of this Unit drew attention to a new clinical entity a solid
lesion found unexpectedly by organ imaging in the liver of a relatively well patient1.
We originally named this a hepatic "incidentaloma", but have felt that the finding
has not been truly incidental in some patients who have had symptoms compatible
with liver pathology. We have been advised by a skilled medical etymologist that
the term "dystychoma" meaning "unlucky tumour" might be more appropri-
ate.
We here report on an extended experience with this entity over 5 years, and
make further suggestions about the epidemiology, diagnosis and management of
the lesion.
MATERIALS AND METHODS
A dystychoma is defined as an unexpected solid lesion in the liver of a patient with a
Karnofsky index of 80% or more, detected or confirmed by organ imaging using
computerised tomography (CT) or ultrasound1. We have not included cystic
291292 J.M. LITTLE ET AL.
lesions, nor solid lesions detected in patients included in screening or follow-up
programmes for chronic hepatitis, bowel or breast cancer or melanoma.
We have recorded information on oral contraceptive use, symptoms, physical
signs, the size and number of lesions in each patient. Patients have undergone a
standard two-phase investigation programme, previously described 1. In the Out
Patient Department, we have obtained liver function tests, hepatitis serology,
alpha foetoprotein (AFP) and carcinoembryonic antigen (CEA) levels and a
labelled red cell blood pool scan. The red cell scan has been confirmed as a reliable,
sensitive and specific diagnostic test for hepatic haemangioma2.
If no diagnosis has been made when these results were available, patients have
been admitted for 2 days to hospital for hepatic angiography and fine needle
aspiration cytology (FNA). If it has seemed appropriate, we have sought a primary
tumour when the FNA has suggested that the hepatic lesion is a secondary tumour.
RESULTS
General
In the 60 month period ending December 1990, we saw 64 patients fulfilling the
defining criteria. Their median age was 47 years, with a range of 17 to 81.
Forty five of the 64 were women, a significance preponderance (chi-square 10.56,
p< .005). Seventeen of the 45 women had taken the oral contraceptive for more
than a year.
Symptom Classification
Symptoms were graded to 3 levels. Level 0 represented no symptoms referable to
the abdomen. Level 1 represented non-specific abdominal discomfort or pain,
without hepatobiliary localisation. Level 2 represented symptoms consistent with
hepatobiliary disease. Symptoms were approximately equally distributed between
the 3 levels (Table 1).
Table 1 Symptom classification
SYMPTOM SCORE NUMBER
0- NO RELEVANT SYMPTOMS
NON-SPECIFIC ABDOMINAL
2- HEPATOBILIARY
20
22
22
Physical Signs
Physical signs were also graded 0 to 2, 0 representing no findings of hepatic
pathology, 1 a palpable liver edge without an apparent liver mass and 2 a
palpable liver mass. The majority of patients had no relevant physical signs (Table
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Table 2 Physical signs
SIGN SCORE NUMBER
0- NO HEPATIC SIGNS
PALPABLE LIVER
2- PALPABLE MASS
51
7
6
Liver Function Tests
In 3 instances, complete liver function tests were not available. Thirty eight of the
remaining 61 patients hard normal liver function tests (serum bilirubin, serum
alkaline phosphatase [SAP], serum alanine-leucine transaminase [ALT], serum
gamma-glutamyl transpeptidase [gamma GT] and serum albumin). One or more
tests were abnormal in 23 patients.
The SAP was less frequently elevated, raised levels being detected in only 13 of
the 61 patients for whom full liver function tests were available.
Tumour Markers
The CEA was raised in 8 of 52 patients in whom its level was estimated. One of
these raised levels appears to represent a false positive, since the patient had a
haemangioma with no evidence of primary or secondary colorectal carcinoma
during a 2 year follow-up. The other 7 reflected the presence of subsequently
confirmed colorectal secondary carcinoma in the liver.
AFP was estimated in 55 patients and was elevated in 4.2 had HCC confirmed,
but in the other 2 these elevations appeared to be false positives. Of the remaining
51 patients with normal levels, 2 were found to have hepatocellular carcinoma
(HCC).
Hepatitis Serology
Hepatitis B serology was obtained for 56 patients, and was positive in 3. Hepatitis C
serology became available only recently, and there are too few results to report.
Number and Size of Lesions
Lesions were single in 46 patients, multiple in 18. The size of individual lesions
varied from 1 to 13 cm in greatest diameter as measured on CT or ultrasound. The
median greatest diameter was 5 cm.
Blood Pool Scans
Blood pool scans were obtained for 58 patients, and were diagnostic of haeman-
gioma in 28. Five additional haemangiomas were diagnosed by arteriography.
Diagnoses
There were 47 non-neoplastic lesions- 33 haemangiomas, 7 focal nodular
hyperplasias (FNH), 5 focal fatty infiltrations and 1 each tuberculous abscess and294 J.M. LITTLE ET AL.
penetrating peptic ulcer. There were 6 benign neoplasms- 5 adenomas and 1
leiomyoma. The remaining 11 patients had malignant neoplasms- 7 colorectal
metastases and 4 hepatocellular carcinomas (HCC). Thus, 47 (74%) had non-
neoplastic lesions, while 11 (17%) had malignancies.
These figures are summarised in the flow chart of Figure 1.
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Figure 1 Flow chart outlining the distribution of diagnoses among the liver lesions.
Diagnostic Phase
A diagnosis was made during the Out Patient phase in 31 patients, the remaining 33
requiring admission to hospital.
Predictors of a Benign or Malignant Tumour
Univariate analysis demonstrated that patients with malignant tumours were
significantly older than those with benign lesions (62 years compared with 43 years,
p< .0001, Mann Whitney). Eight of 13 with a palpable liver or palpable liver mass
had malignancies, compared with 5 of 51 without physical signs of liver enlarge-
ment (p< .0001, Fisher test). Eight of 13 with an elevated SAP had malignancies,HEPATIC DYSTYCHOMA 295
compared with 5 of 48 with measured normal levels (p< .0001, Fisher test). Sex,
the presence or absence of symptoms, the diagnosis of hepatitis, singularity or
multiplicity of lesions and their size did not differ between the groups with benign
and malignant diagnoses.
The influence of small size was examined in more detail. None of 8 patients with
lesions smaller than 3 cm maximum diameter had malignant tumours, compared
with 1 of 13 with lesions from 3-3.9 cm. Thus, only 1 of 21 lesions less than 4 cm in
maximum diameter was malignant, compared with 10 of 43 lesions measuring 4 or
more cm in maximum diameter. None of these differences reached statistical
significance.
When the sizes of lesions which were not haemangiomas were compared, 1 of 7
lesions less than 4 cm maximum diameter proved to be malignant, compared with
10 of 24 larger lesions. This difference was not statistically significant (p= .3717,
Fisher test).
The three factors that were found to distinguish statistically between benign and
malignant lesions were arbitrarily given equal weight and combined in a single
score. Age less than 55 scored 0, age over 55 scored 1; impalpable liver scored 0,
palpable liver or liver mass 1; and normal SAP scored 0, raised SAP 1. The total
score was obtained by simple addition for each patient. There were no malignancies
among patients with total scores of 0; there were 2 among the 18 patients scoring 1;
3 in the 4 patients scoring 2; and all 6 who scored 3 had malignant tumours.
Patient Benefit
An attempt has been made to judge whether each patient has benefited by
improvement in quality or quantity of life, by assessing symptoms before and after
management of the lesion which prompted referral and by assessing the likely
outcome without intervention. Eleven of the 64 patients have unequivocally
benefited, from relief of pain in 7 and from the removal of life threatening
pathology in 4. We have, of course, managed to give reassurance to the majority of
patients whose anxiety was created by the organ imaging investigation.
DISCUSSION
The clinical problem presented by the chance finding of a solid lump in the liver on
organ imaging was described by this unit in 1990 under the name "hepatic
incidentaloma’’1, but we recognise that the term "incidentaloma" is misleading.
The term "dystychoma" meaning "unlucky tumour" was suggested to us by
Dr David S. Johnson, and seems more appropriate to the conditions under which
these lesions are found. Once again, we have been impressed with the frequency
with which organ imaging investigations are being ordered in our medical commun-
ity for conditions that seem quite inappropriate. Twenty of our 64 patients had no
symptoms that could be associated with the liver or biliary system. They had all
presented with self-limiting illnesses, unrelated to their liver lesions. The great
majority (51 of 64) had no physical findings to suggest liver pathology.
The two phase investigation protocol previously described continues to work
reasonably well, and about half our patients have been given a diagnosis and
reassured without admission to hospital because the red cell scan was positive for296 J.M. LITTLE ET AL.
haemangioma. The remainder have needed admission for angiography and,
usually, FNA. Some have needed laparotomy and open biopsy, because the FNA
has produced dysplastic liver cells which did not distinguish between focal nodular
hyperplasia (FNH), adenoma and HCC.
It has been suggested that HIDA scanning might be added to this protocol of
investigation, in order to increase the level of confidence in distinguishing benign
from malignant lesions. Calvet and colleagues3, however, have demonstrated that
some well differentiated HCC’s take up HIDA. Biersack et al. have noted uptake
by FNH, and Strashun and Goldsmith by metastatic breast carcinoma. It seems
unlikely that HIDA scanning will do anything to clarify the diagnostic confusions.
The majority of lesions (74%) were not neoplastic, and the commonest single
diagnosis was haemangioma (52%). Unfortunately, 26% of lesions were neoplas-
tic, and 17% of the total were malignant. The benign tumours must at least be
followed carefully at 6 month intervals to ensure that they are not increasing in
size6’7. Severely symptomatic benign lesions should be removed if it is safe to do so.
This study has confirmed our earlier advice that the clinician should seek the
highest order diagnosis possible, since there are no clinical or biochemical features
that reliably distinguish benign from malignant lesions. There are some clinical
guides which help, but none of them seem wholly reliable. Older patients- more
than 55 years were more likely to have malignancy. Those with enlarged livers or
palpable masses in the liver were more likely to have malignancy, but 5 of 13 with
palpable livers or liver masses had benign lesions. A raised SAP was also an
indicator of malignancy, but once again 5 of 13 with raised SAP had benign lesions.
The combination of these risk factors indicated an increased chance of malignancy.
The absence of all factors was associated with no incidence of malignancy; the
presence of 1 factor carried 1 chance in 9 of malignancy; two factors, 3 chances in 4;
while all 3 factors were associated with 6 malignancies in 6 patients. Small size (less
than 4 cm) was associated with a low incidence of malignancy (1 in 21 patients), but
the difference from the incidence of 10 in 43 with larger lesions was not statistically
significant.
There is no doubt that clinicians will see more of this and similar problems,
created by the ready access to powerful organ imaging devices. One can debate the
validity of performing a CT scan for an episode of self-limited abdominal pain, but
the test will be done unless governments or the profession introduce limits or
guidelines. The finding that only 11 (17%) of the 64 patients in this present study
definitely benefited from the discovery of their liver lesion does not support the
present unselective use of organ imaging to replace history taking and physical
examination.
References
1. Little, J.M., Kenny, J. and Hollands, M.J. (1990) Hepatic incidentalomas: a modern problem.
World J. Surg., 14, 448-451
2. Farlow, D.C., Chapman, P.R., Gruenwald, S.M., Antico, V.F., Farrell, G.C. and Little, J.M.
(1990) Investigation of focal hepatic lesions: is tomographic red blood cell imaging useful? World J.
Surg., 14, 472-477
3. Calvet, X., Pons, F., Bruix, J., Bru, C., Lomena, F., Herranz, R., Brugera, M., Faus, R. and
Rodes, J. (1988) Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular
carcinoma: relationship between detectability and tumour differentiation. J. Nucl. Med., 29, 1916-
20HEPATIC DYSTYCHOMA 297
4. Biersack, H.J., Thelen, M., Torres, J.F., Lackner, K. and Winkler, C.G. (1980) Focal nodular
hyperplasia of the liver as established by 99m-Tc-sulfur colloid and HIDA scintigraphy. Radiology,
137, 187-190
5. Strashun, A. and Goldsmith, S. (1981) Increased focal uptake of Tc-99m-IDA hepatobiliary agent
by a liver metastasis. Clin. Nucl. Med., 6, 295-296
6. Foster, J.H. (1977) Primary benign solid tumours of the liver. Am. J. Surg., 133, 536-541
7. Foster, J.H. (1982) Benign liver tumours. World J. Surg., 6, 25-31
(Accepted by S. Bengmark 12 April 1991)